A vigiPoint characterisation of female versus male reports in VigiBase, the WHO global database of individual case safety reports

General information

This data is supplementary material to the paper by Watson et al. on sex differences in global reporting of adverse drug reactions [1]. Readers are referred to this paper for a detailed description of the context in which the data was generated. Anyone intending to use this data for any purpose should read the publicly available information on the VigiBase source data [2, 3]. The conditions specified in the caveat document [3] must be adhered to.

Source dataset

The dataset published here is based on analyses performed in VigiBase, the WHO global database of individual case safety reports [4]. All reports entered into VigiBase from its inception in 1967 up to 2 January 2018 with patient sex coded as either female or male have been included, except suspected duplicate reports [5]. In total, the source dataset contained 9,056,566 female and 6,012,804 male reports.

Statistical analysis

The characteristics of the female reports were compared to those of the...

数据集基本信息
本数据集为Watson等人发表的关于全球药物不良反应（adverse drug reactions）报告性别差异的学术论文[1]的补充材料。如需了解本数据集生成的具体背景，请参阅该论文。任何拟将本数据集用于任何用途的使用者，均需查阅VigiBase（世界卫生组织个体病例安全报告全球数据库）源数据[2,3]的公开说明文件，并严格遵守警示文档[3]中规定的使用条件。

源数据集
本公开数据集基于VigiBase（世界卫生组织个体病例安全报告全球数据库）[4]中的分析结果构建。本数据集纳入了自1967年VigiBase创立至2018年1月2日期间提交的所有患者性别编码为女性或男性的报告，疑似重复报告[5]除外。最终源数据集共包含9,056,566份女性患者报告与6,012,804份男性患者报告。

统计分析
本研究对女性报告的特征与男性报告的特征进行了对比……